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Background: The significance and utility of measuring the serum eicosapentaenoic acid to arachidonoic acid ratio (EPA/AA) in peripheral artery 
disease (PAD) have not been sufficiently clarified.
methods: Seventy-eight patients with PAD (16 women; mean age, 75.3 ± 8.0 years) were enrolled and divided into 2 groups, those with an EPA/
AA of >0.20 (group-H: n= 73) and those <0.20 (group-L: n= 5). The cardiovascular and limb-ischemic events were assessed during a mean follow-up 
period of 14.3 ± 7.9 months.
results: During the follow-up, 27 patients had cardiovascular events, consisting of 7 deaths, 12 limb-ischemic events, 2 amputations, 2 
percutaneous coronary interventions and 4 miscellaneous events. The incidence of cardiovascular events was greater in group-L than in group-H 
(p<0.05).Kaplan-Meier analysis demonstrated that the patients in group-H had a lesser prevalence of limb-ischemic events than those in group-L 
(p<0.05). The serum EPA concentration correlated with that of the plasma asymmetric dimethylarginine (ADMA), which is an endogenous inhibitor of 
endothelial NO synthase (r= -0.410, p<0.05).
conclusions: In patients with PAD, the measurement of the EPA/AA was useful for further risk stratification, and a low EPA/AA (<0.20) predicted 
following cardiovascular and limb-ischemic events. Underlying endothelial dysfunction in PAD patients with a low EPA/AA might cause those adverse 
outcomes. 
